Drugs / KLH-2109
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT02778919 | May 2016 → Mar 2018 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01533532 | — | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01395940 | — | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01629420 | — | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07378098 | Feb 2026 → Mar 2028 expected | leiomyoma, menstrual disorder | JW Pharmaceutical | Recruiting | No outcome recorded |
| Phase 3 | NCT07015268 | Jun 2025 → Nov 2027 expected | endometriosis | Kissei Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05445167 | Oct 2022 → Feb 2024 | leiomyoma | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05440383 | Oct 2022 → Aug 2024 | leiomyoma | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KLH-2109 | “KLH-2109 tablet” NCT07015268 ↗ |
| Route | Oral | “Oral administration” NCT05445167 ↗ |